A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Dupilumab (Primary) ; Levosalbutamol; Levosalbutamol; Prednisolone; Prednisolone; Prednisone; Prednisone; Salbutamol; Salbutamol
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY ASTHMA VENTURE; VENTURE
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 26 Feb 2024 Results assessing the association between baseline characteristics and OCS reduction in patients with OCS dependent severe asthma , presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 09 Dec 2022 Results (from two studies NCT02528214 and NCT02134028) assessing Long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma published in the Annals of Allergy, Asthma and Immunology
- 09 Nov 2022 Results of post hoc analysis from TRAVERSE (NCT02134028), and VENTURE (NCT02528214) assessing dupilumab efficacy in patients presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research